Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. [electronic resource]
Producer: 20170911Description: 271-281 p. digitalISSN:- 1931-3543
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- B7-H1 Antigen -- antagonists & inhibitors
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Female
- Humans
- Immunotherapy -- adverse effects
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Nivolumab
- Pneumonia -- chemically induced
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Randomized Controlled Trials as Topic
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.